Negative Prognostic Associations of Selective Serotonin Reuptake Inhibitors Use in Hospitalized COVID-19 Patients and Potential Contribution of Cardiovascular Comorbidities DOI

Ivan Papic,

Petra Bistrović, Ivan Krečak

и другие.

Pharmacology, Год журнала: 2024, Номер unknown, С. 1 - 8

Опубликована: Июль 31, 2024

<b><i>Introduction:</i></b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causative agent of disease 2019 (COVID-19), very contagious systemic dominantly affecting the tract. Recent findings oppose earlier suggestions that selective serotonin reuptake inhibitors (SSRIs) might be protective during SARS-CoV-2 infection, prompting current study. <b><i>Methods:</i></b> The institutional registry tertiary referral center was retrospectively evaluated for SSRI use and associated clinical outcomes among hospitalized COVID-19 patients with mostly severe critical disease. <b><i>Results:</i></b> Among 1,558 patients, there were 78 (5%) exposed to hospitalization. users in comparison non-users did not significantly differ their demographic characteristics, comorbidity profile or severity symptoms inflammatory response at admission. In multivariate analyses adjusted clinically meaningful variables, higher risks death, mechanical ventilation, intensive care unit treatment, bacteremia, whereas no significant relationship venous, arterial thrombosis, major bleeding present. Patients less initial presentation, lower burden, platelet count, cumulative presence hyperlipidemia, atrial fibrillation, chronic heart failure nonexposed acetylsalicylic-acid had mortality use. <b><i>Conclusions:</i></b> Findings study validate but also report tendency deterioration, bacteremia patients. These suggest potential contribution cardiovascular comorbidities detrimental course

Язык: Английский

Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials DOI
Marina Sánchez‐Rico, Katayoun Rezaei, Eric J. Lenze

и другие.

Annals of Pharmacotherapy, Год журнала: 2023, Номер unknown

Опубликована: Ноя. 28, 2023

Язык: Английский

Процитировано

4
Negative Prognostic Associations of Selective Serotonin Reuptake Inhibitors Use in Hospitalized COVID-19 Patients and Potential Contribution of Cardiovascular Comorbidities DOI

Ivan Papic,

Petra Bistrović, Ivan Krečak

и другие.

Pharmacology, Год журнала: 2024, Номер unknown, С. 1 - 8

Опубликована: Июль 31, 2024

<b><i>Introduction:</i></b> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causative agent of disease 2019 (COVID-19), very contagious systemic dominantly affecting the tract. Recent findings oppose earlier suggestions that selective serotonin reuptake inhibitors (SSRIs) might be protective during SARS-CoV-2 infection, prompting current study. <b><i>Methods:</i></b> The institutional registry tertiary referral center was retrospectively evaluated for SSRI use and associated clinical outcomes among hospitalized COVID-19 patients with mostly severe critical disease. <b><i>Results:</i></b> Among 1,558 patients, there were 78 (5%) exposed to hospitalization. users in comparison non-users did not significantly differ their demographic characteristics, comorbidity profile or severity symptoms inflammatory response at admission. In multivariate analyses adjusted clinically meaningful variables, higher risks death, mechanical ventilation, intensive care unit treatment, bacteremia, whereas no significant relationship venous, arterial thrombosis, major bleeding present. Patients less initial presentation, lower burden, platelet count, cumulative presence hyperlipidemia, atrial fibrillation, chronic heart failure nonexposed acetylsalicylic-acid had mortality use. <b><i>Conclusions:</i></b> Findings study validate but also report tendency deterioration, bacteremia patients. These suggest potential contribution cardiovascular comorbidities detrimental course

Язык: Английский

Процитировано

0